Compare Coursera Inc (COUR) vs Incyte Corporation (INCY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Coursera Inc vs Incyte Corporation — how do they compare? Coursera Inc trades at $5.57 (market cap $1.50B), while Incyte Corporation trades at $120.58 (market cap $24.54B). The key difference: Incyte Corporation is far larger — about 16.4× Coursera Inc's market cap, and Incyte Corporation is trading nearer its 52-week high, Coursera Inc nearer its low. Which is the better fit depends on your goals.
| COUR | INCY | |
|---|---|---|
Market Cap | $1.50B | $24.54B |
Sector | Consumer Staples | Health |
52-Week High | $12.20 | $129.93 |
52-Week Low | $5.09 | $81.61 |
Enterprise Value | $759.54M | $20.04B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Coursera (COUR) trades at $5.525, down 4.08% today, with a bearish technical signal from moving averages. Revenue grew to $757.5M in 2025, but net losses persist at -$51M. Recent Q2 2026 earnings beat expectations at $0.17 EPS, and the company made a $100M strategic investment in AI education firm LearnVector (Business Wire, July 28, 2026).
The stock offers upside to the $7.70 consensus price target, supported by a majority buy rating from analysts. However, profitability challenges and competitive pressures in online education pose risks. Positive cash flow trends and institutional interest provide a foundation for recovery if execution improves.
Incyte Corporation (INCY) trades at $120.93, down 0.51% on the day, near its 52-week high. The stock shows strong fundamental momentum with Q2 2026 EPS beating estimates at $3.09 versus $2.15 expected, driven by robust Jakafi and Opzelura sales. Revenue growth accelerated to $5.14 billion in 2025, with net income margin expanding to 27.71%. Technical indicators signal a bullish trend with moving averages supporting upside, while oscillators remain neutral.
Outlook remains positive given raised 2026 revenue guidance and recent EU approval for Opzelura, though risks include competitive pressures and reliance on key products. Analyst consensus is bullish with a $122.82 price target, implying modest upside from current levels amid solid institutional ownership trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Coursera Inc
Coursera Inc is a global online learning platform that offers anyone, anywhere access to online courses and degrees from world-class universities and companies. It combines content, data, and technology into a single, unified platform that is customizable and extensible to both individual learners and institutions. The platform will contain a catalog of high-quality content and credentials, content developed by leading university and industry partners, data and machine learning drive personalized Learning, effective marketing, and skills Benchmarking and others.
Read more on COUR →About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →
